Page last updated: 2024-11-02
oxybutynin and Pain
oxybutynin has been researched along with Pain in 77 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our results indicated that incorporating a QR code within additional video education leads to proper use of a fentanyl transdermal patch and relieves pain and anxiety levels in patients with cancer." | 9.34 | Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020) |
| "Local injection of lidocaine provided clinically similar analgesia compared to the lidocaine/tetracaine patch during I&D of skin abscesses in the ED." | 9.19 | Injectable lidocaine provides similar analgesia compared to transdermal lidocaine/tetracaine patch for the incision and drainage of skin abscesses: a randomized, controlled trial. ( Bourne, CL; Brewer, KL; House, J, 2014) |
| "The study did not demonstrate significant differences in pain relief between capsaicin and placebo treatment, although a trend toward pain improvement in capsaicin treated patients was observed 1 month after patch application." | 9.19 | A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. ( Bischoff, JM; Petersen, M; Ringsted, TK; Sommer, C; Uçeyler, N; Werner, MU, 2014) |
| "The primary efficacy endpoint, mean difference between the two treatment arms in an 11-point numerical pain rating scale from baseline to 2 weeks after patch applications, was significantly lower on the capsaicin 8% patch treatment arm [P=0." | 9.19 | Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients. ( Anand, P; Gibbs, JS; Gin-Sing, W; Huson, L; Iddamalgoda, T; Khengar, RH; Libri, V; Pinato, DJ, 2014) |
| "Topical capsaicin 8% was developed for the treatment of peripheral neuropathic pain." | 9.17 | Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. ( Knolle, E; Kovacs, GG; Medwed, S; Scharbert, G; Schemper, M; Zadrazil, M, 2013) |
| "Metastatic breast cancer patients requiring sustained-release oral morphine or controlled-release oral oxycodone(n=9, 2 taking oral morphine, 7 taking oral oxycodone, mean age, 57." | 9.16 | [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. ( Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012) |
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 9.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| "3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia." | 9.15 | Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011) |
| "This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia." | 9.15 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011) |
| "The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain." | 9.14 | Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010) |
| "Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 8.90 | Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 8.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 μg/h) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug." | 8.87 | Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. ( Plosker, GL, 2011) |
| "Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain." | 7.81 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015) |
| "It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)." | 7.80 | A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014) |
| "Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment." | 7.78 | Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012) |
| "Opioid introduction to opioid-naÏve outpatients with cancer pain using the low-dose fentanyl patch (2." | 7.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| " However, oral nonsteroidal anti-inflammatory drugs cause several adverse events, with topical formulations arising as an important alternative." | 6.90 | Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial. ( Daher, MT; Fujiki, EN; Kraychete, DC; Lopes, DG; Nakamoto, A; Netto, NA; Tardini, R, 2019) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 6.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 6.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| "Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs)." | 6.46 | Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. ( Argoff, CE; McCarberg, BH, 2010) |
| "Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population." | 5.91 | Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St ( Ala-Adin, N; Chertin, B; Dothan, D; Gordon, A; Hatumi, S; Kafka, I; Malchi, N; Moldwin, R; Nassar, T; Perez, D; Raisin, G; Shenfeld, O; Touitou, D, 2023) |
| "Fentanyl has a low molecular weight and is lipophilic making it suitable for transdermal administration." | 5.51 | Unusual case of transdermal fentanyl in cachexia. ( Harrison, S; Kay, S; Lam, D; Pickard, J, 2019) |
| "Lidocaine patches are a safe, effective adjunct for rib fracture pain." | 5.37 | Lidocaine patches reduce pain in trauma patients with rib fractures. ( Mayberry, JC; Peck, EG; Schreiber, MA; Zink, KA, 2011) |
| "Our results indicated that incorporating a QR code within additional video education leads to proper use of a fentanyl transdermal patch and relieves pain and anxiety levels in patients with cancer." | 5.34 | Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial. ( Chen, J; Hu, X; Mao, X; Rao, Y; Xuan, Z; Yang, S; Ye, Z; Zhang, Y, 2020) |
| " Patients received stepwise pain treatment in which those who did not use analgesics were randomized to receive either paracetamol (3 g/day) or placebo tablets; those who already used pain treatment were allocated to buprenorphine transdermal system (max." | 5.27 | Effects of pain treatment on sleep in nursing home patients with dementia and depression: A multicenter placebo-controlled randomized clinical trial. ( Bjorvatn, B; Blytt, KM; Flo, E; Husebo, B, 2018) |
| "The primary efficacy endpoint, mean difference between the two treatment arms in an 11-point numerical pain rating scale from baseline to 2 weeks after patch applications, was significantly lower on the capsaicin 8% patch treatment arm [P=0." | 5.19 | Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients. ( Anand, P; Gibbs, JS; Gin-Sing, W; Huson, L; Iddamalgoda, T; Khengar, RH; Libri, V; Pinato, DJ, 2014) |
| "The study did not demonstrate significant differences in pain relief between capsaicin and placebo treatment, although a trend toward pain improvement in capsaicin treated patients was observed 1 month after patch application." | 5.19 | A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. ( Bischoff, JM; Petersen, M; Ringsted, TK; Sommer, C; Uçeyler, N; Werner, MU, 2014) |
| "Local injection of lidocaine provided clinically similar analgesia compared to the lidocaine/tetracaine patch during I&D of skin abscesses in the ED." | 5.19 | Injectable lidocaine provides similar analgesia compared to transdermal lidocaine/tetracaine patch for the incision and drainage of skin abscesses: a randomized, controlled trial. ( Bourne, CL; Brewer, KL; House, J, 2014) |
| " According to a predefined scheme for 8 weeks, all patients in the intervention group received individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline." | 5.19 | The response of agitated behavior to pain management in persons with dementia. ( Aarsland, D; Ballard, C; Cohen-Mansfield, J; Husebo, BS; Seifert, R, 2014) |
| "Pain medication significantly improved pain in the intervention group, with indications that acetaminophen also improved ADL function." | 5.19 | Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial. ( Aarsland, D; Ballard, C; Corbett, A; Husebo, BS; Sandvik, RK; Seifert, R; Selbaek, G, 2014) |
| "Twenty-two healthy males were included in a randomized study to assess the changes in EPs after 110 sweeps of painful electrical stimulation to the median nerve following treatment with buprenorphine, fentanyl or placebo patches." | 5.17 | A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials. ( Andresen, T; Arendt-Nielsen, T; Drewes, AM; Gram, M; Graversen, C; Mørch, CD; Nielsen, AK, 2013) |
| "Topical capsaicin 8% was developed for the treatment of peripheral neuropathic pain." | 5.17 | Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study. ( Knolle, E; Kovacs, GG; Medwed, S; Scharbert, G; Schemper, M; Zadrazil, M, 2013) |
| "Metastatic breast cancer patients requiring sustained-release oral morphine or controlled-release oral oxycodone(n=9, 2 taking oral morphine, 7 taking oral oxycodone, mean age, 57." | 5.16 | [A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer]. ( Fujii, S; Ikeda, M; Koike, Y; Kubo, S; Kurebayashi, J; Mizutou, A; Nakashima, K; Nomura, T; Oota, Y; Saitou, W; Seki, M; Shiiki, S; Shimo, T; Sonoo, H; Tanaka, K; Yamamoto, Y; Yamashita, T, 2012) |
| "Topical lidocaine (5%) leads to sufficient pain relief in only 29%-80% of treated patients, presumably by small-fiber block." | 5.16 | Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. ( Krumova, EK; Maier, C; Westermann, A; Zeller, M, 2012) |
| "VAS pain scores during arterial puncture were comparable in both groups and Rapydan was non-inferior to subcutaneous lidocaine." | 5.16 | Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. ( Dunkler, D; Golescu, A; Grubhofer, G; Hoeferl, M; Hutschala, D; Jaeger, W; Mayer, L; Ruetzler, K; Sessler, DI; Sima, B; You, J, 2012) |
| "3°C cold water), nerve growth factor-induced muscle soreness and intradermal capsaicin-induced hyperalgesia and allodynia." | 5.15 | Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models. ( Andresen, T; Arendt-Nielsen, L; Christrup, LL; Drewes, AM; Foster, DJ; Upton, RN, 2011) |
| "This study evaluated the effects of topical lidocaine on skin sensation and on intradermal capsaicin-induced pain and hyperalgesia." | 5.15 | Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial. ( Lam, VY; Schulteis, G; Wallace, M, 2011) |
| "To assess efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in patients with peripheral neuropathic pain." | 5.15 | Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. ( Lu, B; Murphy, FT; Peppin, JF; Tobias, JK; Vanhove, GF; Webster, LR, 2011) |
| " Of the volunteers who received the nicotine patch, four became anorexic and nauseated and two required anti-emetics." | 5.15 | A randomised double-blind crossover trial of the potential analgesic effect of a transdermal nicotine patch in non-smokers based on objective and subjective assessment. ( Fukada, T; Iwakiri, H; Ozaki, M, 2011) |
| "The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain." | 5.14 | Low doses of transdermal fentanyl in opioid-naive patients with cancer pain. ( Adile, C; Aielli, F; Ferrera, P; Ficorella, C; Mercadante, S; Porzio, G, 2010) |
| "Qutenza (capsaicin) 8% patch is used to treat various neuropathic indications, including postherpetic neuralgia (PHN) and human immunodeficiency virus-associated neuropathy (HIV-AN)." | 4.90 | Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. ( Katz, NP; Mou, J; Paillard, F; Stoker, M; Trudeau, J; Turnbull, B, 2014) |
| "The findings indicate comparability of transdermal buprenorphine and transdermal fentanyl for pain measures with significantly fewer adverse events (nausea and treatment discontinuation due to adverse events) caused by transdermal buprenorphine." | 4.88 | Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain. ( Aune, D; Hernandez, AV; Kleijnen, J; Misso, K; Riemsma, R; Truyers, C; Wolff, RF, 2012) |
| "This article reviews the pharmacology, therapeutic efficacy and tolerability profile of the 7-day lower-dose (5, 10 and 20 μg/h) buprenorphine transdermal patch (BuTrans®, Norspan®) in the management of chronic non-malignant pain, with a focus on European labelling for the drug." | 4.87 | Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain. ( Plosker, GL, 2011) |
| " Treatment was administered using bicalutamide and leuprorelin acetate, while a transdermal fentanyl (TDF) was applied for pain relief." | 4.31 | Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating. ( Ishii, H; Kanai, A; Kokubun, H; Tabata, KI, 2023) |
| "Preclinical Research The aim of this study was to evaluate the efficacy of multiple applications of S(+)-flurbiprofen plaster (SFPP), a novel Nonsteroidal anti-inflammatory drug (NSAID) patch, for the alleviation of inflammatory pain and edema in rat adjuvant-induced arthritis (AIA) model as compared to other NSAID patches." | 3.83 | Topical Anti-Inflammatory and Analgesic Effects of Multiple Applications of S(+)-Flurbiprofen Plaster (SFPP) in a Rat Adjuvant-Induced Arthritis Model. ( Hori, M; Ichihara, T; Kaku, S; Matsumoto, H; Mitani, A; Otsuka, N; Sekine, S; Sugimoto, M; Toda, Y, 2016) |
| "This study was designed to formulate a drug in adhesive transdermal patch with codeine (CDB) and acetaminophen (APAP) that may potentially treat moderate pain in children." | 3.83 | Formulation optimization of a drug in adhesive transdermal analgesic patch. ( Abla, MJ; Banga, AK; Herwadkar, AK; Little, J; Ravula, R, 2016) |
| "Little is known about the efficacy of low-dose transdermal fentanyl (TDF) patches in opioid-naïve patients with moderate-to-severe cancer pain." | 3.81 | The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. ( Hwang, IG; Kang, JH; Kim, JH; Kim, WS; Lee, HR; Lee, HY; Lee, KE; Oh, SY; Park, K; Park, SH; Park, YS; Song, SY, 2015) |
| "This study aimed to investigate whether CYP3A4/5 genetic variants, together with clinical and patient factors, influence serum fentanyl and norfentanyl concentrations and their ratio in cancer pain patients receiving transdermal fentanyl." | 3.80 | Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. ( Bandak, B; Barratt, DT; Christrup, LL; Dale, O; Kaasa, S; Klepstad, P; Somogyi, AA; Tuke, J, 2014) |
| "It is unknown whether nutritional status influences pain intensity in cancer patients receiving a transdermal fentanyl patch (FP)." | 3.80 | A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch. ( Chiba, T; Kimura, Y; Kudo, K; Tairabune, T; Takahashi, H; Takahashi, K; Wakabayashi, G, 2014) |
| "Determining the appropriate dose of transdermal fentanyl (TDF) for the alleviation of cancer pain requires determining the factors causing variations in serum fentanyl concentration after TDF treatment." | 3.78 | Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain. ( Ebinuma, K; Kokubun, H; Matoba, M; Takayanagi, R; Yago, K; Yamada, Y, 2012) |
| "Opioid introduction to opioid-naÏve outpatients with cancer pain using the low-dose fentanyl patch (2." | 3.77 | [Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain]. ( Fujita, S; Fukae, M; Hata, A; Iwamori, S; Kaji, R; Katakami, N; Masuda, Y; Mifune, Y; Nanjo, S; Orita, H; Otsuka, K; Yamatani, T, 2011) |
| " We analyzed data from 5 open-label clinical trials of lidocaine patch 5% in osteoarthritis knee pain and chronic low back pain that were 2 to 12 weeks in duration." | 3.77 | Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events. ( Dworkin, RH; Galer, BS; Gammaitoni, AR; Gould, E; Jensen, MP; Jones, BA; Xiang, Q, 2011) |
| " However, oral nonsteroidal anti-inflammatory drugs cause several adverse events, with topical formulations arising as an important alternative." | 2.90 | Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial. ( Daher, MT; Fujiki, EN; Kraychete, DC; Lopes, DG; Nakamoto, A; Netto, NA; Tardini, R, 2019) |
| "Warts are a common skin disease caused by infection of the human papilloma virus." | 2.87 | Efficacy of a bleomycin microneedle patch for the treatment of warts. ( Baek, JO; Jeong, HR; Kim, HJ; Kim, JS; Lee, SK; Park, JH; Roh, JY; Ryu, HR; Seon-Woo, HS, 2018) |
| " The majority of drug-related adverse events (AEs) included mild dermatitis at the application sites and occurred in 46." | 2.82 | The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study. ( Hoshino, Y; Matsumoto, H; Matsushita, I; Otsuka, N; Yataba, I, 2016) |
| "nausea, constipation, dizziness and headache) were recorded after 6 and 12 days of treatment." | 2.78 | Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail. ( Bu, J; Du, Y; Fu, T; Huang, X; Lin, J; Tan, W; Wang, C; Wei, G, 2013) |
| " The most common adverse events were treatment site related (n=16, 7." | 2.76 | Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury. ( Carr, W; Kuehl, K; Magelli, M; Rovati, S; Yanchick, J, 2011) |
| "Patients with chronic cancer pain were randomly assigned to the conversion from continuous intravenous infusion to transdermal fentanyl using two-step taper of the continuous intravenous infusion in 12 h (12-h method) or the conversion in 6 h (6-h method)." | 2.76 | Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study. ( Hayashi, K; Kamata, M; Kojima, H; Kozai, M; Nomura, M; Sawada, S, 2011) |
| " The primary outcome measure was reduction in ureteral stent symptoms, and the secondary outcome measure was the safety of intravesical instillation of each agent through assessment of drug-related adverse events." | 2.71 | Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. ( Beiko, DT; Brock, GB; Denstedt, JD; Knudsen, BE; Nott, L; Pautler, SE; Razvi, H; Watterson, JD, 2004) |
| "Topical NSAIDs were effective and safe for OA." | 2.58 | Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. ( Doherty, M; Lei, G; Li, J; Li, X; Long, H; Persson, MSM; Sarmanova, A; Wang, Y; Wei, J; Xie, D; Zeng, C; Zhang, W, 2018) |
| "Many types of acute pain have been managed with traditional oral non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 inhibitors (coxibs)." | 2.46 | Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury. ( Argoff, CE; McCarberg, BH, 2010) |
| "Intravesical instillation of TRG-100 was found to be safe and efficient in reducing pain and irritative bladder symptoms in our study population." | 1.91 | Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St ( Ala-Adin, N; Chertin, B; Dothan, D; Gordon, A; Hatumi, S; Kafka, I; Malchi, N; Moldwin, R; Nassar, T; Perez, D; Raisin, G; Shenfeld, O; Touitou, D, 2023) |
| "Its goal was to see how a transdermal fentanyl patch combined with accelerated recovery after surgery (ERAS) affected the treatment efficacy and analgesic effect of liver cancer, as well as to help patients with liver cancer choose the right analgesic treatment and nursing mode." | 1.72 | Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer. ( Fang, S; Lu, G; Xiao, H; Zhu, H, 2022) |
| "Elderly with dementia are prescribed opioids more frequent than elderly without." | 1.56 | The Use of Opioids and Antipsychotics in Elderly with Dementia - Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia? ( Christensen, AN; Gasse, C; Jensen-Dahm, C; Waldemar, G, 2020) |
| " We assessed the proportion of users with prior tolerance stratified by dosage strength of FTS using four definitions of opioid tolerance: ≥30-mg oxycodone equivalents/day in each of 7 consecutive days immediately prior to index; ≥30-mg oxycodone equivalents/day for any 7 days in the 30 days prior to index (secondary); any dose in each of 7 days in the 7 consecutive days immediately prior to index (tertiary); and any dose for any 7 days in the 30 days prior to index (quaternary)." | 1.51 | Assessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA's Sentinel System. ( Cocoros, NM; Ju, J; Kornegay, C; Larochelle, MR; Petrone, AB; Popovic, J; Racoosin, JA, 2019) |
| "Fentanyl has a low molecular weight and is lipophilic making it suitable for transdermal administration." | 1.51 | Unusual case of transdermal fentanyl in cachexia. ( Harrison, S; Kay, S; Lam, D; Pickard, J, 2019) |
| "Fentanyl is an opioid analgesic that is available as injection and transdermal patch products for the management of acute and chronic pain." | 1.51 | Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity. ( Ajjarapu, SS; Bae, J; Dhawan, T; Maurya, A; Murthy, SN; Rangappa, S, 2019) |
| "The prevention of venipuncture-induced cancer pain requires a structured training program, which should reflect the views of nurses in clinical practice." | 1.46 | Barriers to venipuncture-induced pain prevention in cancer patients: a qualitative study. ( Chabloz, C; Chirac, A; Collin, C; Filbet, M; Larkin, P; Monsarrat, L; Rhondali, W; Ruer, M, 2017) |
| " Meanwhile, the ISO-C10 contained patches increased the drug disposition in synovial fluid and enhanced the pharmacodynamic efficacy of the formulation." | 1.42 | Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. ( Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015) |
| " The potential efficacy of these MN for paediatric dosing was investigated via in vitro and in vivo studies." | 1.42 | Potential of hydrogel-forming and dissolving microneedles for use in paediatric populations. ( Caffarel-Salvador, E; Donnelly, RF; McCarthy, HO; McElnay, JC; Mooney, K; Tuan-Mahmood, TM; Woolfson, AD, 2015) |
| "Pain was the most common adverse reaction reported." | 1.40 | Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system. ( Hägg, S; Holmlund, M; Lövborg, H, 2014) |
| "Lidocaine patches are a safe, effective adjunct for rib fracture pain." | 1.37 | Lidocaine patches reduce pain in trauma patients with rib fractures. ( Mayberry, JC; Peck, EG; Schreiber, MA; Zink, KA, 2011) |
Research
Studies (77)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.30) | 29.6817 |
| 2010's | 67 (87.01) | 24.3611 |
| 2020's | 9 (11.69) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Raisin, G | 1 |
| Dothan, D | 1 |
| Perez, D | 1 |
| Ala-Adin, N | 1 |
| Kafka, I | 1 |
| Shenfeld, O | 1 |
| Hatumi, S | 1 |
| Malchi, N | 1 |
| Gordon, A | 2 |
| Touitou, D | 1 |
| Moldwin, R | 1 |
| Nassar, T | 1 |
| Chertin, B | 1 |
| Beiko, DT | 1 |
| Watterson, JD | 1 |
| Knudsen, BE | 1 |
| Nott, L | 1 |
| Pautler, SE | 1 |
| Brock, GB | 1 |
| Razvi, H | 1 |
| Denstedt, JD | 1 |
| Castilla-Casadiego, DA | 1 |
| Miranda-Muñoz, KA | 1 |
| Roberts, JL | 1 |
| Crowell, AD | 1 |
| Gonzalez-Nino, D | 1 |
| Choudhury, D | 1 |
| Aparicio-Solis, FO | 1 |
| Servoss, SL | 1 |
| Rosales, AM | 1 |
| Prinz, G | 1 |
| Zou, M | 1 |
| Zhang, Y | 2 |
| Coetzee, JF | 1 |
| Greenlee, LF | 1 |
| Powell, J | 1 |
| Almodovar, J | 1 |
| Zhu, H | 1 |
| Xiao, H | 1 |
| Lu, G | 1 |
| Fang, S | 1 |
| Nihadha, PM | 1 |
| Chugh, A | 1 |
| Kaur, A | 1 |
| Kumar, S | 1 |
| Naveen, KH | 1 |
| Bhatia, PK | 1 |
| Kumar, P | 1 |
| Chaudhry, K | 1 |
| Dietrich, CG | 1 |
| Kottmann, T | 1 |
| Voß, HW | 1 |
| Lorenz, R | 1 |
| Ishii, H | 3 |
| Kokubun, H | 4 |
| Tabata, KI | 3 |
| Kanai, A | 3 |
| Jensen-Dahm, C | 1 |
| Christensen, AN | 1 |
| Gasse, C | 1 |
| Waldemar, G | 1 |
| Ye, Z | 1 |
| Chen, J | 1 |
| Hu, X | 1 |
| Xuan, Z | 1 |
| Yang, S | 1 |
| Mao, X | 1 |
| Rao, Y | 1 |
| Light, A | 1 |
| Heininger, A | 1 |
| Wessman, K | 1 |
| Frutiger, K | 1 |
| White, RJ | 1 |
| Ryu, HR | 1 |
| Jeong, HR | 1 |
| Seon-Woo, HS | 1 |
| Kim, JS | 1 |
| Lee, SK | 1 |
| Kim, HJ | 1 |
| Baek, JO | 1 |
| Park, JH | 1 |
| Roh, JY | 1 |
| Blytt, KM | 1 |
| Bjorvatn, B | 1 |
| Husebo, B | 1 |
| Flo, E | 1 |
| Zeng, C | 1 |
| Wei, J | 1 |
| Persson, MSM | 1 |
| Sarmanova, A | 1 |
| Doherty, M | 1 |
| Xie, D | 1 |
| Wang, Y | 1 |
| Li, X | 1 |
| Li, J | 1 |
| Long, H | 1 |
| Lei, G | 1 |
| Zhang, W | 1 |
| Cocoros, NM | 1 |
| Larochelle, MR | 1 |
| Popovic, J | 1 |
| Petrone, AB | 1 |
| Kornegay, C | 1 |
| Ju, J | 1 |
| Racoosin, JA | 1 |
| Gisev, N | 1 |
| Pearson, SA | 2 |
| Larance, B | 1 |
| Larney, S | 1 |
| Blanch, B | 1 |
| Degenhardt, L | 1 |
| Feragalli, B | 1 |
| Dugall, M | 1 |
| Luzzi, R | 1 |
| Ledda, A | 1 |
| Hosoi, M | 1 |
| Belcaro, G | 1 |
| Cesarone, MR | 1 |
| Lam, D | 1 |
| Kay, S | 1 |
| Pickard, J | 1 |
| Harrison, S | 1 |
| Ban, T | 1 |
| Hirose, H | 1 |
| Teraura, H | 1 |
| Kotani, K | 1 |
| Gotoh, T | 1 |
| Zheng, D | 1 |
| Narayan, SW | 1 |
| Zoega, H | 1 |
| Litchfield, M | 1 |
| Buckley, NA | 1 |
| Schaffer, AL | 1 |
| Fujiki, EN | 1 |
| Netto, NA | 1 |
| Kraychete, DC | 1 |
| Daher, MT | 1 |
| Tardini, R | 1 |
| Nakamoto, A | 1 |
| Lopes, DG | 1 |
| Yu, T | 1 |
| Zhang, S | 1 |
| Cao, X | 1 |
| Liu, C | 1 |
| Maurya, A | 1 |
| Rangappa, S | 1 |
| Bae, J | 1 |
| Dhawan, T | 1 |
| Ajjarapu, SS | 1 |
| Murthy, SN | 1 |
| Blanco-Antona, F | 1 |
| González-Sarmiento, R | 1 |
| García-Cenador, B | 1 |
| Lozano, FS | 1 |
| Lane, ME | 1 |
| Bermejo, PE | 1 |
| Zea, MA | 1 |
| Alba-Alcántara, L | 1 |
| Ruiz-Huete, C | 1 |
| Gram, M | 1 |
| Graversen, C | 1 |
| Nielsen, AK | 1 |
| Arendt-Nielsen, T | 1 |
| Mørch, CD | 1 |
| Andresen, T | 2 |
| Drewes, AM | 2 |
| Paparella, SF | 1 |
| Husebo, BS | 2 |
| Ballard, C | 2 |
| Cohen-Mansfield, J | 1 |
| Seifert, R | 2 |
| Aarsland, D | 2 |
| Mou, J | 1 |
| Paillard, F | 1 |
| Turnbull, B | 1 |
| Trudeau, J | 1 |
| Stoker, M | 1 |
| Katz, NP | 1 |
| Wang, C | 1 |
| Tan, W | 1 |
| Huang, X | 1 |
| Fu, T | 1 |
| Lin, J | 1 |
| Bu, J | 1 |
| Wei, G | 1 |
| Du, Y | 1 |
| Nalamachu, S | 1 |
| Nalamasu, R | 1 |
| Jenkins, J | 1 |
| Marriott, T | 1 |
| Knolle, E | 1 |
| Zadrazil, M | 1 |
| Kovacs, GG | 1 |
| Medwed, S | 1 |
| Scharbert, G | 1 |
| Schemper, M | 1 |
| Farr, BM | 1 |
| Libri, V | 1 |
| Gibbs, JS | 1 |
| Pinato, DJ | 1 |
| Iddamalgoda, T | 1 |
| Khengar, RH | 1 |
| Gin-Sing, W | 1 |
| Huson, L | 1 |
| Anand, P | 1 |
| Therkleson, T | 1 |
| Barratt, DT | 1 |
| Bandak, B | 1 |
| Klepstad, P | 1 |
| Dale, O | 1 |
| Kaasa, S | 1 |
| Christrup, LL | 2 |
| Tuke, J | 1 |
| Somogyi, AA | 1 |
| Ryazhenov, VV | 1 |
| Abuzarova, GR | 1 |
| Gorokhova, SG | 1 |
| Emchenko, IV | 1 |
| Matveev, NV | 1 |
| Takahashi, H | 1 |
| Chiba, T | 1 |
| Tairabune, T | 1 |
| Kimura, Y | 1 |
| Wakabayashi, G | 1 |
| Takahashi, K | 1 |
| Kudo, K | 1 |
| Sandvik, RK | 1 |
| Selbaek, G | 1 |
| Corbett, A | 1 |
| Bourne, CL | 1 |
| Brewer, KL | 1 |
| House, J | 1 |
| Lövborg, H | 1 |
| Holmlund, M | 1 |
| Hägg, S | 1 |
| Bischoff, JM | 1 |
| Ringsted, TK | 1 |
| Petersen, M | 1 |
| Sommer, C | 1 |
| Uçeyler, N | 1 |
| Werner, MU | 1 |
| Kang, JH | 1 |
| Oh, SY | 1 |
| Song, SY | 1 |
| Lee, HY | 1 |
| Kim, JH | 1 |
| Lee, KE | 1 |
| Lee, HR | 1 |
| Hwang, IG | 1 |
| Park, SH | 1 |
| Kim, WS | 1 |
| Park, YS | 1 |
| Park, K | 1 |
| Caffarel-Salvador, E | 1 |
| Tuan-Mahmood, TM | 1 |
| McElnay, JC | 1 |
| McCarthy, HO | 1 |
| Mooney, K | 1 |
| Woolfson, AD | 1 |
| Donnelly, RF | 1 |
| Chen, Y | 1 |
| Quan, P | 1 |
| Liu, X | 1 |
| Guo, W | 1 |
| Song, W | 1 |
| Cun, D | 1 |
| Wang, Z | 1 |
| Fang, L | 1 |
| Ravula, R | 1 |
| Herwadkar, AK | 1 |
| Abla, MJ | 1 |
| Little, J | 1 |
| Banga, AK | 1 |
| Cheng, YJ | 1 |
| Yataba, I | 1 |
| Otsuka, N | 2 |
| Matsushita, I | 1 |
| Matsumoto, H | 2 |
| Hoshino, Y | 1 |
| Sugimoto, M | 1 |
| Toda, Y | 1 |
| Hori, M | 1 |
| Mitani, A | 1 |
| Ichihara, T | 1 |
| Sekine, S | 1 |
| Kaku, S | 1 |
| Kaur, H | 1 |
| Hwang, JC | 1 |
| Ho, LY | 1 |
| Zhang, X | 1 |
| Ng, HJ | 1 |
| Filbet, M | 1 |
| Larkin, P | 1 |
| Chabloz, C | 1 |
| Chirac, A | 1 |
| Monsarrat, L | 1 |
| Ruer, M | 1 |
| Rhondali, W | 1 |
| Collin, C | 1 |
| Nomura, M | 1 |
| Kamata, M | 1 |
| Kojima, H | 1 |
| Hayashi, K | 1 |
| Kozai, M | 1 |
| Sawada, S | 1 |
| McCarberg, BH | 1 |
| Argoff, CE | 1 |
| LoVecchio, F | 1 |
| Ramos, L | 1 |
| Dworkin, RH | 1 |
| Jensen, MP | 1 |
| Gould, E | 1 |
| Jones, BA | 1 |
| Xiang, Q | 1 |
| Galer, BS | 1 |
| Gammaitoni, AR | 1 |
| Lam, VY | 1 |
| Wallace, M | 1 |
| Schulteis, G | 1 |
| Botterman, J | 1 |
| Criel, N | 1 |
| Mercadante, S | 1 |
| Porzio, G | 1 |
| Ferrera, P | 1 |
| Aielli, F | 1 |
| Adile, C | 1 |
| Ficorella, C | 1 |
| Upton, RN | 1 |
| Foster, DJ | 1 |
| Arendt-Nielsen, L | 1 |
| Hata, A | 1 |
| Katakami, N | 1 |
| Masuda, Y | 1 |
| Nanjo, S | 1 |
| Otsuka, K | 1 |
| Kaji, R | 1 |
| Fujita, S | 1 |
| Iwamori, S | 1 |
| Mifune, Y | 1 |
| Orita, H | 1 |
| Fukae, M | 1 |
| Yamatani, T | 1 |
| Kuehl, K | 1 |
| Carr, W | 1 |
| Yanchick, J | 1 |
| Magelli, M | 2 |
| Rovati, S | 2 |
| Webster, LR | 1 |
| Peppin, JF | 1 |
| Murphy, FT | 1 |
| Lu, B | 1 |
| Tobias, JK | 1 |
| Vanhove, GF | 1 |
| Zink, KA | 1 |
| Mayberry, JC | 1 |
| Peck, EG | 1 |
| Schreiber, MA | 1 |
| Brewer, AR | 1 |
| Pierchala, LA | 1 |
| Yanchick, JK | 1 |
| Fukada, T | 1 |
| Iwakiri, H | 1 |
| Ozaki, M | 1 |
| Garbe, E | 1 |
| Jobski, K | 1 |
| Schmid, U | 1 |
| Maathuis, MH | 1 |
| Dijkstra, DD | 1 |
| Barkin, RL | 1 |
| Barkin, SJ | 1 |
| Irving, GA | 1 |
| Krumova, EK | 1 |
| Zeller, M | 1 |
| Westermann, A | 1 |
| Maier, C | 1 |
| Przeklasa-Muszyńska, A | 1 |
| Dobrogowski, J | 1 |
| Plosker, GL | 1 |
| Wolff, RF | 1 |
| Aune, D | 1 |
| Truyers, C | 1 |
| Hernandez, AV | 1 |
| Misso, K | 1 |
| Riemsma, R | 1 |
| Kleijnen, J | 1 |
| Harrison, AP | 1 |
| Hansen, SH | 1 |
| Bartels, EM | 1 |
| Ikeda, M | 1 |
| Sonoo, H | 1 |
| Kurebayashi, J | 1 |
| Oota, Y | 1 |
| Fujii, S | 1 |
| Shimo, T | 1 |
| Mizutou, A | 1 |
| Seki, M | 1 |
| Saitou, W | 1 |
| Yamashita, T | 1 |
| Koike, Y | 1 |
| Yamamoto, Y | 1 |
| Shiiki, S | 1 |
| Nakashima, K | 1 |
| Tanaka, K | 1 |
| Nomura, T | 1 |
| Kubo, S | 1 |
| Ebinuma, K | 1 |
| Matoba, M | 1 |
| Takayanagi, R | 1 |
| Yamada, Y | 1 |
| Yago, K | 1 |
| Ruetzler, K | 1 |
| Sima, B | 1 |
| Mayer, L | 1 |
| Golescu, A | 1 |
| Dunkler, D | 1 |
| Jaeger, W | 1 |
| Hoeferl, M | 1 |
| You, J | 1 |
| Sessler, DI | 1 |
| Grubhofer, G | 1 |
| Hutschala, D | 1 |
| Takakuwa, O | 1 |
| Oguri, T | 1 |
| Maeno, K | 1 |
| Yokoyama, M | 1 |
| Hijikata, H | 1 |
| Uemura, T | 1 |
| Ozasa, H | 1 |
| Ohkubo, H | 1 |
| Miyazaki, M | 1 |
| Niimi, A | 1 |
Clinical Trials (9)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Randomized, Pilot Study of Preoperative Anti-Inflammatory Therapy for Ureteral Stent Symptoms[NCT03638999] | Early Phase 1 | 36 participants (Anticipated) | Interventional | 2018-07-31 | Recruiting | ||
| The Impact of Pain on Behavioural Disturbances in Patients With Moderate and Severe Dementia. A Cluster Randomized Trial[NCT01021696] | Phase 2/Phase 3 | 352 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Double-blind, Randomized, Crossover Clinical Study to Assess the Efficacy of Qutenza® for the Reduction of Site Pain Caused by Continuous Subcutaneous Infusion of Remodulin®, in Pulmonary Arterial Hypertension Patients[NCT01393795] | Phase 2 | 11 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Trial of Intranasal Fentanyl Versus Placebo as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage in the Emergency[NCT03872700] | Phase 3 | 49 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| [NCT01699854] | Phase 3 | 50 participants (Anticipated) | Interventional | 2012-08-31 | Terminated (stopped due to Expiration of the placebo patch) | ||
| Transdermal Microneedle Patch To Enhance Topical Anaesthesia Before Intravenous Line Insertion for Blood Transfusion In Paediatric Thalassemia Patients[NCT05078463] | Phase 2 | 20 participants (Actual) | Interventional | 2021-09-15 | Completed | ||
| Preventive Application Of Lidocaine Patch In Adjunction To Intravenous Morphine Analgesia For Management Of Post-Thoracotomy Pain: Results Of A Randomized, Double Blind, Placebo Controlled Study[NCT02751619] | 90 participants (Actual) | Interventional | 2013-01-31 | Completed | |||
| A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain[NCT00082316] | Phase 2 | 0 participants | Interventional | Completed | |||
| Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297] | 301 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
NRS Pain Score After Blunt Dissection
Patient reported NRS pain scores after Blunt Dissection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.1 |
| Placebo | 4.4 |
NRS Pain Score After Irrigation
Patient reported NRS pain scores after Irrigation. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.4 |
| Placebo | 2.6 |
NRS Pain Score After Lidocaine Injection
Patient reported NRS pain scores after Lidocaine injection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Following Lidocaine injection measured once anytime up to 12 minutes after intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.4 |
| Placebo | 8.0 |
NRS Pain Score After Packing of Abscess
Patient reported pain after Packing of abscess. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once at the time of completion of application of the bandage, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.5 |
| Placebo | 3.9 |
NRS Pain Score Following Incision
Patient reported NRS pain scores following Incision. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.9 |
| Placebo | 3.9 |
Numerical Rating Scale (NRS) Pain Score at Baseline
Patient reported pain scores at baseline. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.3 |
| Placebo | 8.1 |
Numerical Rating Scale (NRS) Pain Score for Overall Procedure
Patient reported pain scores for overall Procedure assessed immediately after placement of dressing at the end of procedure. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once following placement of dressing at completion of procedure, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 6.2 |
| Placebo | 7.0 |
Reviews
7 reviews available for oxybutynin and Pain
| Article | Year |
|---|---|
Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents, Non-Steroidal; Bayes Theorem; Humans; Network M | 2018 |
The transdermal delivery of fentanyl.
Topics: Administration, Cutaneous; Analgesics; Analgesics, Opioid; Buprenorphine; Clinical Trials as Topic; | 2013 |
Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients.
Topics: Adult; Aged; Aged, 80 and over; Capsaicin; Databases, Factual; Dose-Response Relationship, Drug; Dou | 2014 |
Topical diclofenac epolamine patch 1.3% for treatment of acute pain caused by soft tissue injury.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Contusions; Diclofenac; Humans; Pain; Soft Tiss | 2010 |
Management of chronic noncancer pain in depressed patients.
Topics: Acetaminophen; Analgesics; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, N | 2011 |
Buprenorphine 5, 10 and 20 μg/h transdermal patch: a review of its use in the management of chronic non-malignant pain.
Topics: Analgesics, Opioid; Buprenorphine; Chronic Disease; Dose-Response Relationship, Drug; Humans; Pain; | 2011 |
Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain.
Topics: Administration, Oral; Analgesics, Opioid; Buprenorphine; Chronic Pain; Constipation; Fentanyl; Human | 2012 |
Trials
28 trials available for oxybutynin and Pain
| Article | Year |
|---|---|
Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy.
Topics: Administration, Intravesical; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Double-Bl | 2004 |
Transdermal fentanyl patch versus standard analgesia in postoperative oral submucous fibrosis patients: a triple blinded, randomised control trial.
Topics: Analgesia; Analgesics, Opioid; Fentanyl; Humans; Oral Submucous Fibrosis; Pain; Transdermal Patch | 2022 |
Video Education Reduces Pain and Anxiety Levels in Cancer Patients Who First Use Fentanyl Transdermal Patch: A Randomized Controlled Trial.
Topics: Adult; Aged; Aged, 80 and over; Anxiety; Female; Fentanyl; Health Education; Humans; Male; Middle Ag | 2020 |
Efficacy of a bleomycin microneedle patch for the treatment of warts.
Topics: Adolescent; Adult; Antiviral Agents; Bleomycin; Child; Child, Preschool; Cryotherapy; Female; Humans | 2018 |
Effects of pain treatment on sleep in nursing home patients with dementia and depression: A multicenter placebo-controlled randomized clinical trial.
Topics: Acetaminophen; Adult; Aged; Analgesics; Buprenorphine; Dementia; Depressive Disorder; Double-Blind M | 2018 |
Efficacy and safety of loxoprofen sodium topical patch for the treatment of pain in patients with minor acute traumatic limb injuries in Brazil: a randomized, double-blind, noninferiority trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brazil; Double-Blind Method; Extre | 2019 |
Iontophoretic delivery of transdermal patches containi.
Topics: Administration, Cutaneous; Anesthetics, Local; Animals; Child; Child, Preschool; Dialysis; Drug Comp | 2019 |
A novel approach to pharmaco-EEG for investigating analgesics: assessment of spectral indices in single-sweep evoked brain potentials.
Topics: Adult; Analgesics, Opioid; Brain; Buprenorphine; Cross-Over Studies; Data Interpretation, Statistica | 2013 |
The response of agitated behavior to pain management in persons with dementia.
Topics: Acetaminophen; Aged, 80 and over; Analgesics; Buprenorphine; Delayed-Action Preparations; Dementia; | 2014 |
Curative effect of Dingqi analgesic patch on cancer pain: a single-blind randomized controlled trail.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics; Drugs, Chinese Herbal; Female; Humans; Male; | 2013 |
Comparison of cooling and EMLA to reduce the burning pain during capsaicin 8% patch application: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Capsaicin; Cryotherapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Lidocaine; Li | 2013 |
Capsaicin 8% patch for treprostinil subcutaneous infusion site pain in pulmonary hypertension patients.
Topics: Adult; Aged; Antihypertensive Agents; Capsaicin; Double-Blind Method; Epoprostenol; Female; Humans; | 2014 |
Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial.
Topics: Acetaminophen; Activities of Daily Living; Aged; Aged, 80 and over; Analgesics; Buprenorphine; Clini | 2014 |
Injectable lidocaine provides similar analgesia compared to transdermal lidocaine/tetracaine patch for the incision and drainage of skin abscesses: a randomized, controlled trial.
Topics: Abscess; Adolescent; Adult; Anesthesia, Local; Anesthetics, Local; Double-Blind Method; Female; Huma | 2014 |
A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Capsaicin; Female; Hernia, Inguinal; Humans; Male; Middle Aged; Pain; Pain Management; | 2014 |
Lidocaine Skin Patch (Lidopat® 5%) Is Effective in the Treatment of Traumatic Rib Fractures: A Prospective Double-Blinded and Vehicle-Controlled Study.
Topics: Analgesics, Opioid; Anesthetics, Local; Double-Blind Method; Drug Utilization; Female; Humans; Lengt | 2016 |
The Long-Term Safety of S-Flurbiprofen Plaster for Osteoarthritis Patients: An Open-Label, 52-Week Study.
Topics: Administration, Topical; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis, Contact; Female; | 2016 |
Six- versus 12-h conversion method from intravenous to transdermal fentanyl in chronic cancer pain: a randomized study.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Chronic Disease; Double-Blind Method; Female; F | 2011 |
Effects of lidocaine patch on intradermal capsaicin-induced pain: a double-blind, controlled trial.
Topics: Anesthetics, Local; Capsaicin; Double-Blind Method; Humans; Hyperalgesia; Injections, Intradermal; L | 2011 |
Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.
Topics: Aged; Analgesia; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Fentanyl; Humans; Mal | 2010 |
Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Capsaicin; Cold Temperature; Cross-Over Studies; Dose-Resp | 2011 |
Analgesic efficacy and safety of the diclofenac epolamine topical patch 1.3% (DETP) in minor soft tissue injury.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non | 2011 |
Efficacy, safety, and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain.
Topics: Aged; Anesthetics, Local; Capsaicin; Diabetic Neuropathies; Drug-Related Side Effects and Adverse Re | 2011 |
A randomised double-blind crossover trial of the potential analgesic effect of a transdermal nicotine patch in non-smokers based on objective and subjective assessment.
Topics: Administration, Cutaneous; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Nau | 2011 |
Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers.
Topics: Adult; Aged; Anesthetics, Local; Double-Blind Method; Female; Humans; Hyperalgesia; Lidocaine; Male; | 2012 |
Transdermal buprenorphine in the treatment of cancer and non-cancer pain - the results of multicenter studies in Poland.
Topics: Analgesics, Opioid; Buprenorphine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Huma | 2011 |
[A pilot study of the reduced effects of adverse events caused by oral morphine and oxycodone after rotating to fentanyl patch in patients with metastatic breast cancer].
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Breast Neoplasms; Drug Therapy, Combin | 2012 |
Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anesthesia, Local; Anesthetic | 2012 |
Other Studies
42 other studies available for oxybutynin and Pain
| Article | Year |
|---|---|
Open Label, Pilot Evaluation of the Safety and Efficacy of Intravesical Sustained Release System of Lidocaine and Oxybutynin (TRG-100) for Patients With Interstitial Cystitis/Bladder Pain Syndrome, Overactive Bladder and Patients With Retained Ureteral St
Topics: Administration, Intravesical; Cystitis, Interstitial; Delayed-Action Preparations; Humans; Lidocaine | 2023 |
Biodegradable microneedle patch for delivery of meloxicam for managing pain in cattle.
Topics: Administration, Cutaneous; Animals; Cattle; Chitosan; Drug Delivery Systems; Meloxicam; Needles; Pai | 2022 |
Effect of Transdermal Fentanyl Patch Combined with Enhanced Recovery after Surgery on the Curative Effect and Analgesic Effect of Liver Cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Cancer Pain; Enhanced Recovery After Surgery; Fentany | 2022 |
Aloe Vera-Containing Matrix in Transdermal Fentanyl Therapy Improves Adhesion, Skin Tolerance and Quality of Life: Results of a German Multicenter Study with a New Fentanyl Patch.
Topics: Administration, Cutaneous; Aloe; Analgesics, Opioid; Fentanyl; Humans; Pain; Quality of Life; Transd | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
Case Reports of Transdermal Fentanyl Patch Administration Difficulties in Cancer Patients with Excess Sweating.
Topics: Administration, Cutaneous; Adult; Analgesics, Opioid; Fentanyl; Humans; Male; Middle Aged; Neoplasms | 2023 |
The Use of Opioids and Antipsychotics in Elderly with Dementia - Have Opioids Replaced Antipsychotics in Treating Behavioral Symptoms in Dementia?
Topics: Aged; Aged, 80 and over; Analgesics, Opioid; Antipsychotic Agents; Behavioral Symptoms; Cross-Sectio | 2020 |
8% Capsaicin Patch as Analgesia for Severe Treprostinil Infusion Site Pain.
Topics: Aged; Antihypertensive Agents; Capsaicin; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Inf | 2017 |
Assessment of prior opioid tolerance among new users of fentanyl transdermal system in FDA's Sentinel System.
Topics: Administration, Cutaneous; Adolescent; Adult; Analgesics, Opioid; Child; Child, Preschool; Delayed-A | 2019 |
A population-based study of transdermal fentanyl initiation in Australian clinical practice.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Australia | 2019 |
Pycnogenol®: supplementary management of symptomatic osteoarthritis with a patch. An observational registry study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Flavonoids; Humans; Inflammation; Knee; Male | 2019 |
Unusual case of transdermal fentanyl in cachexia.
Topics: Analgesics, Opioid; Cachexia; Female; Fentanyl; Hospices; Humans; Middle Aged; Naloxone; Narcotic An | 2019 |
Multiple physician visits after restricting the prescription of compresses/patches in a Japanese rural community: preliminary results.
Topics: Administration, Topical; Aged; Aged, 80 and over; Female; Humans; Male; Office Visits; Osteoarthriti | 2019 |
Anticipating the effects of restricting high-dose preparations of strong opioids in Australia: A population-based analysis to inform the current policy debate.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analgesics, Opioid; Australia; Buprenorphin | 2019 |
Evaluation of soluble fentanyl microneedles for loco-regional anti-nociceptive activity.
Topics: Analgesics, Opioid; Animals; Drug Liberation; Fentanyl; Male; Microinjections; Needles; Pain; Rats, | 2019 |
Transdermal Buprenorphine for Controlling Pain in Patients with Critical Lower-Limb Ischemia.
Topics: Administration, Cutaneous; Analgesics, Opioid; Buprenorphine; Humans; Ischemia; Pain; Pain Managemen | 2020 |
[Local effects of transdermal treatment with rotigotine].
Topics: Aged; Antiparkinson Agents; Dopamine Agonists; Drug Evaluation; Drug Therapy, Combination; Equipment | 2013 |
A serious threat to patient safety: the unintended misuse of FentaNYL patches.
Topics: Administration, Cutaneous; Aged; Analgesics, Opioid; Child, Preschool; Fatal Outcome; Female; Fentan | 2013 |
An open-label pilot study evaluating the effectiveness of the heated lidocaine/tetracaine patch for the treatment of pain associated with carpal tunnel syndrome.
Topics: Administration, Cutaneous; Adult; Carpal Tunnel Syndrome; Drug Combinations; Female; Hot Temperature | 2014 |
Unclear study methods still confusing readers despite CONSORT guidelines (e.g., lidocaine patch does relieve pain of covered rib fractures).
Topics: Case-Control Studies; Guideline Adherence; Humans; Lidocaine; Pain; Pain Measurement; Periodicals as | 2014 |
Topical Ginger Treatment With a Compress or Patch for Osteoarthritis Symptoms.
Topics: Administration, Topical; Aged; Female; Humans; Male; Middle Aged; New Zealand; Osteoarthritis; Pain; | 2014 |
Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; ATP Binding Cassette Transporter, Subfamily D, M | 2014 |
[Use of fendivia transdermal therapeutic system in Russian patients with malignant neoplasms during palliative care: pharmacoeconomic aspects].
Topics: Ambulances; Analgesics, Opioid; Cost-Benefit Analysis; Economics, Pharmaceutical; Fentanyl; Health C | 2014 |
A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Humans; Male; Middle Aged; Neo | 2014 |
Medication errors related to transdermal opioid patches: lessons from a regional incident reporting system.
Topics: Adverse Drug Reaction Reporting Systems; Analgesics, Opioid; Buprenorphine; Fentanyl; Humans; Medica | 2014 |
The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Female; Fentanyl; Hum | 2015 |
Potential of hydrogel-forming and dissolving microneedles for use in paediatric populations.
Topics: Administration, Cutaneous; Adolescent; Analgesics; Animals; Caffeine; Child; Female; Humans; Hydroge | 2015 |
Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutic | 2015 |
Formulation optimization of a drug in adhesive transdermal analgesic patch.
Topics: Acetaminophen; Adhesives; Administration, Cutaneous; Analgesics; Animals; Chemistry, Pharmaceutical; | 2016 |
Topical Anti-Inflammatory and Analgesic Effects of Multiple Applications of S(+)-Flurbiprofen Plaster (SFPP) in a Rat Adjuvant-Induced Arthritis Model.
Topics: Administration, Cutaneous; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 2016 |
Extensive subcutaneous haematoma associated with transdermal analgesic patch in a haemophilia A patient with inhibitor.
Topics: Adult; Analgesics, Opioid; Antibodies, Neutralizing; Factor VIIa; Hematoma; Hemoglobins; Hemophilia | 2016 |
Barriers to venipuncture-induced pain prevention in cancer patients: a qualitative study.
Topics: Adult; Analgesia; Attitude of Health Personnel; Clinical Competence; Clinical Protocols; Female; Hum | 2017 |
Suicide by Duragesic transdermal fentanyl patch toxicity.
Topics: Adult; Analgesics, Opioid; Female; Fentanyl; Humans; Pain; Suicide; Transdermal Patch | 2011 |
Treatment satisfaction in osteoarthritis and chronic low back pain: the role of pain, physical and emotional functioning, sleep, and adverse events.
Topics: Anesthetics, Local; Chronic Disease; Clinical Trials as Topic; Female; Humans; Lidocaine; Low Back P | 2011 |
Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics, Opioid; | 2011 |
[Direct low-dose fentanyl patch (2.1mg) introduction for opioid naïve outpatients with cancer pain].
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Constipation; Female; Fentanyl; Humans; Male; Mi | 2011 |
Lidocaine patches reduce pain in trauma patients with rib fractures.
Topics: Anesthetics, Local; Female; Humans; Lidocaine; Male; Middle Aged; Oregon; Pain; Retrospective Studie | 2011 |
Gastrointestinal tolerability of diclofenac epolamine topical patch 1.3%: a pooled analysis of 14 clinical studies.
Topics: Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Gastrointesti | 2011 |
Utilisation of transdermal fentanyl in Germany from 2004 to 2006.
Topics: Aged; Analgesics, Opioid; Databases, Factual; Dose-Response Relationship, Drug; Female; Fentanyl; Ge | 2012 |
Disaster after the plaster. Fentanyl withdrawal symptoms in a curable hospice patient.
Topics: Aged, 80 and over; Analgesics, Opioid; Colonic Neoplasms; Drug Administration Schedule; Female; Fent | 2011 |
Transdermal opioid patches for pain treatment in ancient Greece.
Topics: Analgesics, Opioid; Animals; Greece, Ancient; History, Ancient; Humans; Male; Mice; Pain; Transderma | 2012 |
Population pharmacokinetics of transdermal fentanyl in patients with cancer-related pain.
Topics: Administration, Cutaneous; Adult; Aged; Analgesics, Opioid; Cytochrome P-450 CYP3A; Dose-Response Re | 2012 |
Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.
Topics: Administration, Cutaneous; Analgesics, Opioid; Citric Acid; Fentanyl; Humans; Lung Neoplasms; Neopla | 2013 |